- Announced new clinical data for two programs utilizing ARCUS validating safety and efficacy for Precision's in vivo gene editing approach - Announced initial data from first cohort in the ongoing Phase 1 ELIMINATE-B trial evaluating PBGENE-HBV; initial safety data presented at EASL; ongoing